Rilpivirine (BioDeep_00000858509)
代谢物信息卡片
Rilpivirine
化学式: C22H18N6 (366.15928679999996)
中文名称: 利匹韦林
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC1=CC(=CC(=C1NC2=NC(=NC=C2)NC3=CC=C(C=C3)C#N)C)C=CC#N
InChI: InChI=1S/C22H18N6/c1-15-12-18(4-3-10-23)13-16(2)21(15)27-20-9-11-25-22(28-20)26-19-7-5-17(14-24)6-8-19/h3-9,11-13H,1-2H3,(H2,25,26,27,28)/b4-3+
描述信息
J - Antiinfectives for systemic use > J05 - Antivirals for systemic use > J05A - Direct acting antivirals > J05AG - Non-nucleoside reverse transcriptase inhibitors
C471 - Enzyme Inhibitor > C1589 - Reverse Transcriptase Inhibitor > C97453 - Non-nucleoside Reverse Transcriptase Inhibitor
D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D018894 - Reverse Transcriptase Inhibitors
D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D044966 - Anti-Retroviral Agents
D004791 - Enzyme Inhibitors > D019384 - Nucleic Acid Synthesis Inhibitors
C254 - Anti-Infective Agent > C281 - Antiviral Agent
同义名列表
1 个代谢物同义名
数据库引用编号
7 个数据库交叉引用编号
- ChEBI: CHEBI:68606
- KEGGdrug: D09720
- PubChem: 6451164
- DrugBank: DB08864
- ChEMBL: CHEMBL175691
- MeSH: Rilpivirine
- CAS: 500287-72-9
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Eisuke Adachi, Makoto Saito, Amato Otani, Michiko Koga, Hiroshi Yotsuyanagi. Brief communications: changes in inflammatory biomarkers and lipid profiles after switching to long-acting cabotegravir plus rilpivirine.
AIDS research and therapy.
2024 01; 21(1):1. doi:
10.1186/s12981-023-00590-4. [PMID: 38173008] - Filippo Lagi, Andrea Giacomelli, Vanni Borghi, Arturo Ciccullo, Lucia Taramasso, Giordano Madeddu, Gabriella D'Ettorre, Andrea Giacometti, Filippo Ducci, Andrea De Vito, Rachele Pincino, Simona Di Giambenedetto, Cristina Mussini, Spinello Antinori, Gaetana Sterrantino. Efficacy and tolerability of dolutegravir/lamivudine versus dolutegravir/rilpivirine in switching from a three-drug regimen based on nonnucleoside reverse transcriptase inhibitors: A retrospective cohort study.
Journal of medical virology.
2023 10; 95(10):e29149. doi:
10.1002/jmv.29149. [PMID: 37805832] - Di Wu, Mengjie Si, Hui Yi Xue, Ngoc T Tran, Kamel Khalili, Rafal Kaminski, Ho Lun Wong. Lipid nanocarrier targeting activated macrophages for antiretroviral therapy of HIV reservoir.
Nanomedicine (London, England).
2023 08; 18(20):1343-1360. doi:
10.2217/nnm-2023-0120. [PMID: 37815117] - Paolo Maggi, Elena Delfina Ricci, Canio Vito Martinelli, Giuseppe Vittorio De Socio, Nicola Squillace, Chiara Molteni, Addolorata Masiello, Giancarlo Orofino, Barbara Menzaghi, Rita Bellagamba, Francesca Vichi, Benedetto Maurizio Celesia, Giordano Madeddu, Giovanni Francesco Pellicanò, Maria Aurora Carleo, Antonio Cascio, Andrea Parisini, Lucia Taramasso, Laura Valsecchi, Leonardo Calza, Stefano Rusconi, Eleonora Sarchi, Salvatore Martini, Olivia Bargiacchi, Katia Falasca, Giovanni Cenderello, Sergio Ferrara, Antonio Di Biagio, Paolo Bonfanti. Lipids and Transaminase in Antiretroviral-Treatment-Experienced People Living with HIV, Switching to a Doravirine-Based vs. a Rilpivirine-Based Regimen: Data from a Real-Life Setting.
Viruses.
2023 07; 15(7):. doi:
10.3390/v15071612. [PMID: 37515298] - Paolo Maggi, Elena Delfina Ricci, Stefania Cicalini, Giovanni Francesco Pellicanò, Benedetto Maurizio Celesia, Francesca Vichi, Antonio Cascio, Eleonora Sarchi, Giancarlo Orofino, Nicola Squillace, Giordano Madeddu, Giuseppe Vittorio De Socio, Olivia Bargiacchi, Chiara Molteni, Addolorata Masiello, Annalisa Saracino, Barbara Menzaghi, Katia Falasca, Lucia Taramasso, Antonio Di Biagio, Paolo Bonfanti. Lipids and transaminase elevations in ARV-experienced PLWH switching to a doravirine-based regimen from rilpivirine or other regimens.
BMC infectious diseases.
2023 Apr; 23(1):227. doi:
10.1186/s12879-023-08191-2. [PMID: 37059996] - R Palacios, C Gómez-Ayerbe, J L Casado, F Tejerina, M L Montes, M Castaño, A Ocampo, D Rial, E Ribera, M J Galindo, C Hidalgo, C Fariñas, M Montero, T Payeras, F Fanjul, J de la Torre, J Santos. Efficacy and safety of dolutegravir/rilpivirine in real-world clinical practice. GeSIDA study 1119.
HIV medicine.
2023 Apr; ?(?):. doi:
10.1111/hiv.13489. [PMID: 37016556] - Carmen Hidalgo-Tenorio, David Vinuesa, Coral García-Vallecillos, Leopoldo Muñoz-Medina, Sergio Sequera, Rosario Javier, Miguel Ángel López-Ruz, Svetlana Sadyrbaeva-Dolgova, Juan Pasquau. Rildo: Real-World Multicenter Study on the Effectiveness and Safety of Single-Tablet Regimen of Dolutegravir plus Rilpivirine in Treatment-Experienced People Living with HIV.
Viruses.
2022 11; 14(12):. doi:
10.3390/v14122626. [PMID: 36560630] - Inken K Ramöller, Marco T A Abbate, Lalitkumar K Vora, Aaron R J Hutton, Ke Peng, Fabiana Volpe-Zanutto, Ismaiel A Tekko, Kurtis Moffatt, Alejandro J Paredes, Helen O McCarthy, Ryan F Donnelly. HPLC-MS method for simultaneous quantification of the antiretroviral agents rilpivirine and cabotegravir in rat plasma and tissues.
Journal of pharmaceutical and biomedical analysis.
2022 May; 213(?):114698. doi:
10.1016/j.jpba.2022.114698. [PMID: 35259714] - Vasiliki Chounta, Sonya J Snedecor, Sterling Wu, Nicolas Van de Velde. Indirect comparison of 48-week efficacy and safety of long-acting cabotegravir and rilpivirine maintenance every 8 weeks with daily oral standard of care antiretroviral therapy in participants with virologically suppressed HIV-1-infection.
BMC infectious diseases.
2022 May; 22(1):428. doi:
10.1186/s12879-022-07243-3. [PMID: 35508986] - Sangeeta Pandey, Yanyang Hu, Lane R Bushman, Jose Castillo-Mancilla, Peter L Anderson, R Graham Cooks. Miniature mass spectrometer-based point-of-care assay for cabotegravir and rilpivirine in whole blood.
Analytical and bioanalytical chemistry.
2022 May; 414(11):3387-3395. doi:
10.1007/s00216-022-03954-3. [PMID: 35169905] - Dora Luise, Emanuela Lattuada, Sebastiano Rizzardo, Stefano Nicolè, Lorenza Lambertenghi, Ilaria Coledan, Silvia Gambino, Rossella Gottardo, Massimiliano Lanzafame, Sandro Vento. Short-cycle therapy in HIV-infected adults: rilpivirine combination 4 days on/3 days off therapy.
The Journal of antimicrobial chemotherapy.
2022 02; 77(3):747-752. doi:
10.1093/jac/dkab442. [PMID: 34849955] - Susan Swindells, Thomas Lutz, Lelanie Van Zyl, Norma Porteiro, Matthias Stoll, Essack Mitha, Alyssa Shon, Paul Benn, Jenny O Huang, Conn M Harrington, Kai Hove, Susan L Ford, Christine L Talarico, Vasiliki Chounta, Herta Crauwels, Rodica Van Solingen-Ristea, Simon Vanveggel, David A Margolis, Kimberly Y Smith, Kati Vandermeulen, William R Spreen. Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment.
AIDS (London, England).
2022 02; 36(2):185-194. doi:
10.1097/qad.0000000000003025. [PMID: 34261093] - Anthony Mills, Gary J Richmond, Cheryl Newman, Olayemi Osiyemi, Jerry Cade, Cynthia Brinson, Jerome De Vente, David A Margolis, Kenneth C Sutton, Viviana Wilches, Sarah Hatch, Jeremy Roberts, Cynthia McCoig, Cindy Garris, Kati Vandermeulen, William R Spreen. Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapy.
AIDS (London, England).
2022 02; 36(2):195-203. doi:
10.1097/qad.0000000000003085. [PMID: 34652287] - Behnaz Eshaghi, Josiane Fofana, Sarah B Nodder, Suryaram Gummuluru, Björn M Reinhard. Virus-Mimicking Polymer Nanoparticles Targeting CD169+ Macrophages as Long-Acting Nanocarriers for Combination Antiretrovirals.
ACS applied materials & interfaces.
2022 Jan; 14(2):2488-2500. doi:
10.1021/acsami.1c17415. [PMID: 34995059] - Edgar T Overton, Gary Richmond, Giuliano Rizzardini, Hans Jaeger, Catherine Orrell, Firaya Nagimova, Fritz Bredeek, Miguel García Deltoro, Susan Swindells, Jaime Federico Andrade-Villanueva, Alexander Wong, Marie-Aude Khuong-Josses, Rodica Van Solingen-Ristea, Veerle van Eygen, Herta Crauwels, Susan Ford, Christine Talarico, Paul Benn, Yuanyuan Wang, Krischan J Hudson, Vasiliki Chounta, Amy Cutrell, Parul Patel, Mark Shaefer, David A Margolis, Kimberly Y Smith, Simon Vanveggel, William Spreen. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.
Lancet (London, England).
2021 12; 396(10267):1994-2005. doi:
10.1016/s0140-6736(20)32666-0. [PMID: 33308425] - M Neyens, H M Crauwels, J J Perez-Ruixo, S Rossenu. Population pharmacokinetics of the rilpivirine long-acting formulation after intramuscular dosing in healthy subjects and people living with HIV.
The Journal of antimicrobial chemotherapy.
2021 11; 76(12):3255-3262. doi:
10.1093/jac/dkab338. [PMID: 34510179] - Hans Jaeger, Edgar T Overton, Gary Richmond, Giuliano Rizzardini, Jaime Federico Andrade-Villanueva, Rosie Mngqibisa, Antonio Ocampo Hermida, Anders Thalme, Elena Belonosova, Faïza Ajana, Paul D Benn, Yuanyuan Wang, Krischan J Hudson, Carlos Martín Español, Susan L Ford, Herta Crauwels, David A Margolis, Christine L Talarico, Kimberly Y Smith, Veerle van Eygen, Rodica Van Solingen-Ristea, Simon Vanveggel, William R Spreen. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.
The lancet. HIV.
2021 11; 8(11):e679-e689. doi:
10.1016/s2352-3018(21)00185-5. [PMID: 34648734] - Chloe Orkin, Enrique Bernal Morell, Darrell H S Tan, Harold Katner, Hans-Jürgen Stellbrink, Elena Belonosova, Rebecca DeMoor, Sandy Griffith, Shanker Thiagarajah, Rodica Van Solingen-Ristea, Susan L Ford, Herta Crauwels, Parul Patel, Amy Cutrell, Kimberly Y Smith, Kati Vandermeulen, Eileen Birmingham, Marty St Clair, William R Spreen, Ronald D'Amico. Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study.
The lancet. HIV.
2021 11; 8(11):e668-e678. doi:
10.1016/s2352-3018(21)00184-3. [PMID: 34656207] - Jean Michel Molina, Luminita Ene, Pedro Cahn, Gerd Fätkenheuer, Eric Van Wijngaerden, Johan Lombaard, Natalia Zakharova, Veerle Van Eygen, Simon Vanveggel, Rodica Van Solingen-Ristea. Long-term safety and efficacy of rilpivirine in combination with nucleoside/nucleotide reverse transcriptase inhibitors in HIV-1 infected patients: 336-week rollover study of phase 2b and 3 clinical studies.
Antiviral therapy.
2021 11; 26(6-8):95-105. doi:
10.1177/13596535211062388. [PMID: 35485339] - Z C Lim, G S Hoo, J H Ang, C B Teng, L W Ang, C C Lee, Y S Leo, H L Law, O T Ng, C S Wong. Safety and effectiveness of switching to Abacavir/Lamivudine plus rilpivirine for maintenance therapy in virologically suppressed HIV-1 individuals in Singapore (SEALS).
AIDS research and therapy.
2021 11; 18(1):80. doi:
10.1186/s12981-021-00402-7. [PMID: 34724931] - Fuad Ameen, Estari Mamidala, Rakesh Davella, Shravan Vallala. Rilpivirine inhibits SARS-CoV-2 protein targets: A potential multi-target drug.
Journal of infection and public health.
2021 Oct; 14(10):1454-1460. doi:
10.1016/j.jiph.2021.07.012. [PMID: 34326009] - Sarah-Jane Anderson, Chiung-Yuan Hsu, Huang-Tz Ou, Nai-Ying Ko, Chun-Ting Yang, Sara Lopes. Cost-Effectiveness of Juluca for Human Immunodeficiency Virus Infection Treatment in Virologically Suppressed Adults in Taiwan.
Value in health regional issues.
2021 May; 24(?):216-223. doi:
10.1016/j.vhri.2020.11.010. [PMID: 33857719] - Chloe Orkin, Shinichi Oka, Patrick Philibert, Cynthia Brinson, Ayesha Bassa, Denis Gusev, Olaf Degen, Juan González García, Enrique Bernal Morell, Darrell H S Tan, Ronald D'Amico, David Dorey, Sandy Griffith, Shanker Thiagarajah, Marty St Clair, Rodica Van Solingen-Ristea, Herta Crauwels, Susan L Ford, Parul Patel, Vasiliki Chounta, Simon Vanveggel, Amy Cutrell, Veerle Van Eygen, Kati Vandermeulen, David A Margolis, Kimberly Y Smith, William R Spreen. Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study.
The lancet. HIV.
2021 04; 8(4):e185-e196. doi:
10.1016/s2352-3018(20)30340-4. [PMID: 33794181] - Emuri Abe, Lambert Assoumou, Pierre de Truchis, Karine Amat, Séverine Gibowski, Guillaume Gras, Jonathan Bellet, Juliette Saillard, Christine Katlama, Dominique Costagliola, Pierre-Marie Girard, Roland Landman, Jean-Claude Alvarez. Pharmacological data of a successful 4-days-a-week regimen in HIV antiretroviral therapy (ANRS 162-4D trial).
British journal of clinical pharmacology.
2021 04; 87(4):1930-1939. doi:
10.1111/bcp.14586. [PMID: 33010058] - Herana Kamal Seneviratne, Joseph Tillotson, Julie M Lade, Linda-Gail Bekker, Sue Li, Subash Pathak, Jessica Justman, Nyaradzo Mgodi, Shobha Swaminathan, Nirupama Sista, Jennifer Farrior, Paul Richardson, Craig W Hendrix, Namandje N Bumpus. Metabolism of Long-Acting Rilpivirine After Intramuscular Injection: HIV Prevention Trials Network Study 076 (HPTN 076).
AIDS research and human retroviruses.
2021 03; 37(3):173-183. doi:
10.1089/aid.2020.0155. [PMID: 33191765] - Valérie Potard, Sebastien Gallien, Ana Canestri, Dominique Costagliola. Use of rilpivirine in HIV-1-infected individuals in routine clinical practice from 2012 to 2017 in France.
The Journal of antimicrobial chemotherapy.
2021 01; 76(2):467-476. doi:
10.1093/jac/dkaa449. [PMID: 33257955] - Nadège Néant, Minh Patrick Lê, Naïm Bouazza, Florence Gattacceca, Yazdan Yazdanpanah, Catherine Dhiver, Sylvie Bregigeon, Saadia Mokhtari, Gilles Peytavin, Catherine Tamalet, Diane Descamps, Bruno Lacarelle, Caroline Solas. Usefulness of therapeutic drug monitoring of rilpivirine and its relationship with virologic response and resistance in a cohort of naive and pretreated HIV-infected patients.
British journal of clinical pharmacology.
2020 12; 86(12):2404-2413. doi:
10.1111/bcp.14344. [PMID: 32374049] - Giuliano Rizzardini, Edgar T Overton, Chloe Orkin, Susan Swindells, Keikawus Arasteh, Miguel Górgolas Hernández-Mora, Vadim Pokrovsky, Pierre-Marie Girard, Shinichi Oka, Jaime F Andrade-Villanueva, Gary J Richmond, Axel Baumgarten, Mar Masiá, Gulam Latiff, Sandy Griffith, Conn M Harrington, Krischan J Hudson, Marty St Clair, Christine L Talarico, Parul Patel, Amy Cutrell, Veerle Van Eygen, Ronald D'Amico, Joseph M Mrus, Sterling Wu, Susan L Ford, Ken Chow, Jeremy Roberts, Angela Wills, Nicola Walters, Simon Vanveggel, Rodica Van Solingen-Ristea, Herta Crauwels, Kimberly Y Smith, William R Spreen, David A Margolis. Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials.
Journal of acquired immune deficiency syndromes (1999).
2020 12; 85(4):498-506. doi:
10.1097/qai.0000000000002466. [PMID: 33136751] - Dhanashree H Surve, Anil B Jindal. Recent advances in long-acting nanoformulations for delivery of antiretroviral drugs.
Journal of controlled release : official journal of the Controlled Release Society.
2020 08; 324(?):379-404. doi:
10.1016/j.jconrel.2020.05.022. [PMID: 32461114] - Charlotte S Hakkers, Anne Marie Hermans, Erik M van Maarseveen, Charlotte E Teunissen, Inge M W Verberk, Joop E Arends, Andy I M Hoepelman. High efavirenz levels but not neurofilament light plasma levels are associated with poor neurocognitive functioning in asymptomatic HIV patients.
Journal of neurovirology.
2020 08; 26(4):572-580. doi:
10.1007/s13365-020-00860-1. [PMID: 32524424] - Shalini Behl, Abdu Adem, Arif Hussain, Jaipaul Singh. Effect of the anti-retroviral drug, rilpivirine, on human subcutaneous adipose cells and its nutritional management using quercetin.
Molecular and cellular biochemistry.
2020 Aug; 471(1-2):1-13. doi:
10.1007/s11010-020-03744-4. [PMID: 32533464] - Jordi Navarro, Ana González-Cordón, José Luís Casado, Jose I Bernardino, Pere Domingo, Joaquin Portilla, Josep Maria Llibre, Joan Colomer, David Rial-Crestelo, Pilar Vizcarra, Adrià Curran, Esteban Martínez, Esteban Ribera. Effectiveness of boosted darunavir plus rilpivirine in patients with long-lasting HIV-1 infection: DARIL study.
The Journal of antimicrobial chemotherapy.
2020 07; 75(7):1955-1960. doi:
10.1093/jac/dkaa072. [PMID: 32134108] - Perrine Courlet, Susana Alves Saldanha, Matthias Cavassini, Catia Marzolini, Eva Choong, Chantal Csajka, Huldrych F Günthard, Pascal André, Thierry Buclin, Vincent Desfontaine, Laurent Arthur Decosterd. Development and validation of a multiplex UHPLC-MS/MS assay with stable isotopic internal standards for the monitoring of the plasma concentrations of the antiretroviral drugs bictegravir, cabotegravir, doravirine, and rilpivirine in people living with HIV.
Journal of mass spectrometry : JMS.
2020 Jun; 55(6):e4506. doi:
10.1002/jms.4506. [PMID: 32160389] - Lin Sun, Alexej Dick, Megan E Meuser, Tianguang Huang, Waleed A Zalloum, Chin-Ho Chen, Srinivasulu Cherukupalli, Shujing Xu, Xiao Ding, Ping Gao, Dongwei Kang, Erik De Clercq, Christophe Pannecouque, Simon Cocklin, Kuo-Hsiung Lee, Xinyong Liu, Peng Zhan. Design, Synthesis, and Mechanism Study of Benzenesulfonamide-Containing Phenylalanine Derivatives as Novel HIV-1 Capsid Inhibitors with Improved Antiviral Activities.
Journal of medicinal chemistry.
2020 05; 63(9):4790-4810. doi:
10.1021/acs.jmedchem.0c00015. [PMID: 32298111] - Manuel Vélez-Díaz-Pallarés, Teresa Gramage-Caro, Miguel Ángel Rodríguez-Sagrado, Beatriz Montero-Llorente, Teresa Bermejo-Vicedo. Satisfaction and knowledge among patients with HIV after switching from tenofovir to tenofovir alafenamide in regimens containing emtricitabine and rilpivirine.
Biomedica : revista del Instituto Nacional de Salud.
2020 05; 40(Supl. 1):132-138. doi:
10.7705/biomedica.4989. [PMID: 32463615] - Pierre Frange, Roland Tubiana, Jeanne Sibiude, Ana Canestri, Cédric Arvieux, Cécile Brunet-Cartier, Laurent Cotte, Jacques Reynes, Laurent Mandelbrot, Josiane Warszawski, Jérôme Le Chenadec. Rilpivirine in HIV-1-positive women initiating pregnancy: to switch or not to switch?.
The Journal of antimicrobial chemotherapy.
2020 05; 75(5):1324-1331. doi:
10.1093/jac/dkaa017. [PMID: 32157283] - F Maggiolo, N Gianotti, L Comi, E Di Filippo, L Fumagalli, S Nozza, L Galli, D Valenti, M Rizzi, A Castagna. Rilpivirine plus cobicistat-boosted darunavir as a two-drug switch regimen in HIV-infected, virologically suppressed subjects on steady standard three-drug therapy: a randomized, controlled, non-inferiority trial (PROBE 2).
The Journal of antimicrobial chemotherapy.
2020 05; 75(5):1332-1337. doi:
10.1093/jac/dkaa018. [PMID: 32129855] - Kulissara Palanuphap, Somnuek Sungkanuparph. Switching protease inhibitors to rilpivirine in HIV-positive individuals with complete viral suppression and without prior HIV drug resistance in a resource-limited setting: a randomized controlled trial.
Journal of the International AIDS Society.
2020 04; 23(4):e25462. doi:
10.1002/jia2.25462. [PMID: 32277868] - Dario Cattaneo, Tiziana Formenti, Bronzino Isabella, Carlo Filice, Marta Fusi, Cristina Gervasoni. Effects of ursodeoxycholic acid on rilpivirine plasma trough concentrations: a case report.
European journal of clinical pharmacology.
2020 Apr; 76(4):605-606. doi:
10.1007/s00228-019-02825-8. [PMID: 31897533] - Kevin Melody, Chandra N Roy, Christopher Kline, Mackenzie L Cottrell, Dwayne Evans, Kathleen Shutt, Pleuni S Pennings, Brandon F Keele, Moses Bility, Angela D M Kashuba, Zandrea Ambrose. Long-Acting Rilpivirine (RPV) Preexposure Prophylaxis Does Not Inhibit Vaginal Transmission of RPV-Resistant HIV-1 or Select for High-Frequency Drug Resistance in Humanized Mice.
Journal of virology.
2020 03; 94(8):. doi:
10.1128/jvi.01912-19. [PMID: 31969438] - Susan Swindells, Jaime-Federico Andrade-Villanueva, Gary J Richmond, Giuliano Rizzardini, Axel Baumgarten, Mar Masiá, Gulam Latiff, Vadim Pokrovsky, Fritz Bredeek, Graham Smith, Pedro Cahn, Yeon-Sook Kim, Susan L Ford, Christine L Talarico, Parul Patel, Vasiliki Chounta, Herta Crauwels, Wim Parys, Simon Vanveggel, Joseph Mrus, Jenny Huang, Conn M Harrington, Krischan J Hudson, David A Margolis, Kimberly Y Smith, Peter E Williams, William R Spreen. Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression.
The New England journal of medicine.
2020 03; 382(12):1112-1123. doi:
10.1056/nejmoa1904398. [PMID: 32130809] - Scott L Letendre, Anthony Mills, Debbie Hagins, Susan Swindells, Franco Felizarta, Jerome Devente, Christopher Bettacchi, Yu Lou, Susan Ford, Kenneth Sutton, Jafar Sadik Shaik, Herta Crauwels, Ronald D'Amico, Parul Patel. Pharmacokinetics and antiviral activity of cabotegravir and rilpivirine in cerebrospinal fluid following long-acting injectable administration in HIV-infected adults.
The Journal of antimicrobial chemotherapy.
2020 03; 75(3):648-655. doi:
10.1093/jac/dkz504. [PMID: 31873746] - Bhavesh D Kevadiya, Brendan Ottemann, Insiya Z Mukadam, Laura Castellanos, Kristen Sikora, James R Hilaire, Jatin Machhi, Jonathan Herskovitz, Dhruvkumar Soni, Mahmudul Hasan, Wenting Zhang, Sarella Anandakumar, Jered Garrison, JoEllyn McMillan, Benson Edagwa, R Lee Mosley, Richard W Vachet, Howard E Gendelman. Rod-shape theranostic nanoparticles facilitate antiretroviral drug biodistribution and activity in human immunodeficiency virus susceptible cells and tissues.
Theranostics.
2020; 10(2):630-656. doi:
10.7150/thno.39847. [PMID: 31903142] - Frank A Post, Lisa Hamzah. Correcting eGFR for the effects of ART on tubular creatinine secretion: does one size fit all?.
Antiviral therapy.
2020; 25(5):241-243. doi:
10.3851/imp3378. [PMID: 33459634] - Rajith K R Rajoli, Charles Flexner, Justin Chiong, Andrew Owen, Ryan F Donnelly, Eneko Larrañeta, Marco Siccardi. Modelling the intradermal delivery of microneedle array patches for long-acting antiretrovirals using PBPK.
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
2019 Nov; 144(?):101-109. doi:
10.1016/j.ejpb.2019.09.011. [PMID: 31525446] - J L Casado, M Monsalvo, P Vizcarra, M Fontecha, S Serrano-Villar, S Moreno. Evaluation of kidney function in HIV-infected patients receiving an antiretroviral regimen containing one or two inhibitors of the tubular secretion of creatinine.
HIV medicine.
2019 11; 20(10):648-656. doi:
10.1111/hiv.12784. [PMID: 31321875] - James R Hilaire, Aditya N Bade, Brady Sillman, Nagsen Gautam, Jonathan Herskovitz, Bhagya Laxmi Dyavar Shetty, Melinda S Wojtkiewicz, Adam Szlachetka, Benjamin G Lamberty, Sruthi Sravanam, Howard S Fox, Yazen Alnouti, Prasanta K Dash, JoEllyn M McMillan, Benson J Edagwa, Howard E Gendelman. Creation of a long-acting rilpivirine prodrug nanoformulation.
Journal of controlled release : official journal of the Controlled Release Society.
2019 10; 311-312(?):201-211. doi:
10.1016/j.jconrel.2019.09.001. [PMID: 31491432] - Michael Aboud, Chloe Orkin, Daniel Podzamczer, Johannes R Bogner, David Baker, Marie-Aude Khuong-Josses, David Parks, Konstantinos Angelis, Lesley P Kahl, Elizabeth A Blair, Kimberly Adkison, Mark Underwood, Jessica E Matthews, Brian Wynne, Kati Vandermeulen, Martin Gartland, Kimberly Smith. Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies.
The lancet. HIV.
2019 09; 6(9):e576-e587. doi:
10.1016/s2352-3018(19)30149-3. [PMID: 31307948] - Ross D Cranston, Charlene S Dezzutti, Aaron Siegel, Jarret Engstrom, Cory Shetler, Nicola Richardson-Harman, Kaleab Z Abebe, David Back, Laura Else, Deidre Egan, Saye Khoo, James E Egan, Ronald Stall, Peter Williams, Rhonda M Brand, Urvi M Parikh, Ian McGowan. A Multiple Dose Phase 1 Assessment of Rilpivirine Long Acting in a Model of Preexposure Prophylaxis Against HIV.
AIDS research and human retroviruses.
2019 09; 35(9):794-804. doi:
10.1089/aid.2018.0265. [PMID: 31146534] - Sphamandla Ntshangase, Sipho Mdanda, Tricia Naicker, Hendrik G Kruger, Thavendran Govender, Sooraj Baijnath. Rilpivirine as a potential candidate for the treatment of HIV-associated neurocognitive disorders (HAND).
Journal of molecular histology.
2019 Aug; 50(4):295-303. doi:
10.1007/s10735-019-09826-y. [PMID: 31011919] - Nadège Néant, Caroline Solas, Naïm Bouazza, Minh Patrick Lê, Yazdan Yazdanpanah, Catherine Dhiver, Sylvie Bregigeon, Saadia Mokhtari, Gilles Peytavin, Catherine Tamalet, Diane Descamps, Bruno Lacarelle, Florence Gattacceca. Concentration-response model of rilpivirine in a cohort of HIV-1-infected naive and pre-treated patients.
The Journal of antimicrobial chemotherapy.
2019 07; 74(7):1992-2002. doi:
10.1093/jac/dkz141. [PMID: 31225609] - Suyun Lei, Lizhu Hong, Cuixian Yang, Shuang Zhang, Yanyun Zhang, Shizhen Huang, Ronghui Xie, Xia Li, Qing Ma, Huiqin Li. Effect of rilpivirine on the pharmacokinetics of methadone in HIV-Infected Chinese patients.
Expert review of clinical pharmacology.
2019 Jun; 12(6):565-571. doi:
10.1080/17512433.2019.1608523. [PMID: 31091116] - Shalini Behl, Abdu Adem, Arif Hussain, Jaipaul Singh. Effects of rilpivirine, 17β-estradiol and β-naphthoflavone on the inflammatory status of release of adipocytokines in 3T3-L1 adipocytes in vitro.
Molecular biology reports.
2019 Jun; 46(3):2643-2655. doi:
10.1007/s11033-019-04671-4. [PMID: 30927158] - Maelíosa T C Mc Crudden, Eneko Larrañeta, Annie Clark, Courtney Jarrahian, Annie Rein-Weston, Benjamin Creelman, Yolanda Moyo, Sophie Lachau-Durand, Nico Niemeijer, Peter Williams, Helen O McCarthy, Darin Zehrung, Ryan F Donnelly. Design, Formulation, and Evaluation of Novel Dissolving Microarray Patches Containing Rilpivirine for Intravaginal Delivery.
Advanced healthcare materials.
2019 05; 8(9):e1801510. doi:
10.1002/adhm.201801510. [PMID: 30838804] - Sivaporn Gatechompol, Anchalee Avihingsanon, Tanakorn Apornpong, Win Min Han, Stephen J Kerr, Kiat Ruxrungtham. Efficacy and improvement of lipid profile after switching to rilpivirine in resource limited setting: real life clinical practice.
AIDS research and therapy.
2019 04; 16(1):7. doi:
10.1186/s12981-019-0222-6. [PMID: 30953533] - Jose L Casado, Marta Monsalvo, María Fontecha, Pilar Vizcarra, Miguel A Rodriguez, María Jesús Vivancos, Santiago Moreno. Dolutegravir plus rilpivirine as dual regimen in virologically suppressed HIV-1 infected patients in a clinical setting.
HIV research & clinical practice.
2019 04; 20(2):64-72. doi:
10.1080/15284336.2019.1628460. [PMID: 31303142] - Chloé Dimeglio, Stéphanie Raymond, Florence Nicot, Nicolas Jeanne, Romain Carcenac, Caroline Lefebvre, Jacques Izopet. Impact of the mutational load on the virological response to a first-line rilpivirine-based regimen.
The Journal of antimicrobial chemotherapy.
2019 03; 74(3):718-721. doi:
10.1093/jac/dky495. [PMID: 30535228] - Lucia Taramasso, Antonio Di Biagio, Niccolò Riccardi, Federica Briano, Elisa Di Filippo, Laura Comi, Sara Mora, Mauro Giacomini, Andrea Gori, Franco Maggiolo. Lipid profile changings after switching from rilpivirine/tenofovir disoproxil fumarate/emtricitabine to rilpivirine/tenofovir alafenamide/emtricitabine: Different effects in patients with or without baseline hypercholesterolemia.
PloS one.
2019; 14(10):e0223181. doi:
10.1371/journal.pone.0223181. [PMID: 31603906] - Arturo Ciccullo, Gianmaria Baldin, Amedeo Capetti, Stefano Rusconi, Gaetana Sterrantino, Gabriella d'Ettorre, Manuela Colafigli, Sara Modica, Filippo Lagi, Andrea Giacomelli, Maria Vittoria Cossu, Sibilla Restelli, Andrea De Luca, Simona Di Giambenedetto. A comparison between two dolutegravir-based two-drug regimens as switch strategies in a multicentre cohort of HIV-1-infected patients.
Antiviral therapy.
2019; 24(1):63-67. doi:
10.3851/imp3270. [PMID: 30277466] - Maelíosa T C Mc Crudden, Eneko Larrañeta, Annie Clark, Courtney Jarrahian, Annie Rein-Weston, Sophie Lachau-Durand, Nico Niemeijer, Peter Williams, Clement Haeck, Helen O McCarthy, Darin Zehrung, Ryan F Donnelly. Design, formulation and evaluation of novel dissolving microarray patches containing a long-acting rilpivirine nanosuspension.
Journal of controlled release : official journal of the Controlled Release Society.
2018 12; 292(?):119-129. doi:
10.1016/j.jconrel.2018.11.002. [PMID: 30395897] - Brendan M Ottemann, Austin J Helmink, Wenting Zhang, Insiya Mukadam, Christopher Woldstad, James R Hilaire, Yutong Liu, JoEllyn M McMillan, Benson J Edagwa, R Lee Mosley, Jered C Garrison, Bhavesh D Kevadiya, Howard E Gendelman. Bioimaging predictors of rilpivirine biodistribution and antiretroviral activities.
Biomaterials.
2018 12; 185(?):174-193. doi:
10.1016/j.biomaterials.2018.09.018. [PMID: 30245386] - Nadia Galizzi, Laura Galli, Andrea Poli, Vincenzo Spagnuolo, Antonella Castagna, Nicola Gianotti. Glomerular filtration rate estimated by cystatin C formulas in HIV-1 patients treated with dolutegravir, rilpivirine or cobicistat.
The new microbiologica.
2018 10; 41(4):256-261. doi:
NULL. [PMID: 30252923] - Rashmi Mehta, Allen Wolstenholme, Kristin Di Lullo, Caifeng Fu, Shashidhar Joshi, Herta Crauwels, Naomi Givens, Simon Vanveggel, Brian Wynne, Kimberly Adkison. Bioequivalence of a Fixed-Dose Combination Tablet of the Complete Two-Drug Regimen of Dolutegravir and Rilpivirine for Treatment of HIV-1 Infection.
Antimicrobial agents and chemotherapy.
2018 09; 62(9):. doi:
10.1128/aac.00748-18. [PMID: 29987139] - A Ocampo, P Domingo, P Fernández, J Diz, J R Barberá, M A Sepúlveda, X Salgado, M Rodriguez, J Santos, M Yzusqui, M I Mayorga, J F Lorenzo, A Bahamonde, P Bachiller, E Martínez, N Rozas, C Torres, A Muñoz, A Casado, D Podzamczer. Lipid changes and tolerability in a cohort of adult HIV-infected patients who switched to rilpivirine/emtricitabine/tenofovir due to intolerance to previous combination ART: the PRO-STR study.
The Journal of antimicrobial chemotherapy.
2018 08; 73(8):2171-2176. doi:
10.1093/jac/dky175. [PMID: 29788066] - Lucia Taramasso, Paola Tatarelli, Elena Ricci, Giordano Madeddu, Barbara Menzaghi, Nicola Squillace, Giuseppe Vittorio De Socio, Canio Martinelli, Roberto Gulminetti, Paolo Maggi, Giancarlo Orofino, Francesca Vichi, Antonio Di Biagio, Paolo Bonfanti. Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA).
BMC infectious diseases.
2018 07; 18(1):357. doi:
10.1186/s12879-018-3268-5. [PMID: 30064371] - Ahizechukwu C Eke, Nahida Chakhtoura, Angela Kashuba, Brookie M Best, Craig Sykes, Jiajia Wang, Alice M Stek, Elizabeth Smith, Samantha Calabrese, Edmund V Capparelli, Mark Mirochnick. Rilpivirine Plasma and Cervicovaginal Concentrations in Women During Pregnancy and Postpartum.
Journal of acquired immune deficiency syndromes (1999).
2018 07; 78(3):308-313. doi:
10.1097/qai.0000000000001677. [PMID: 29528944] - Hsin-Yun Sun, Sui-Yuan Chang, Chien-Ching Hung. Dolutegravir-rilpivirine coformulation.
Current opinion in HIV and AIDS.
2018 07; 13(4):320-325. doi:
10.1097/coh.0000000000000466. [PMID: 29553948] - Francesca Ferretti, Marta Boffito. Rilpivirine long-acting for the prevention and treatment of HIV infection.
Current opinion in HIV and AIDS.
2018 07; 13(4):300-307. doi:
10.1097/coh.0000000000000474. [PMID: 29794818] - Jose L Casado, Marta Monsalvo, Aurora M Rojo, María Fontecha, Miguel A Rodriguez-Sagrado. Dolutegravir and rilpivirine for the maintenance treatment of virologically suppressed HIV-1 infection.
Expert review of clinical pharmacology.
2018 Jun; 11(6):561-570. doi:
10.1080/17512433.2018.1478726. [PMID: 29775399] - Mehmet Gumustas, Mehmet Gokhan Caglayan, Feyyaz Onur, Sibel A Ozkan. Simultaneous determination and validation of emtricitabine, rilpivirine and tenofovir from biological samples using LC and CE methods.
Biomedical chromatography : BMC.
2018 Apr; 32(4):. doi:
10.1002/bmc.4158. [PMID: 29216682] - Josep M Llibre, Chien-Ching Hung, Cynthia Brinson, Francesco Castelli, Pierre-Marie Girard, Lesley P Kahl, Elizabeth A Blair, Kostas Angelis, Brian Wynne, Kati Vandermeulen, Mark Underwood, Kim Smith, Martin Gartland, Michael Aboud. Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies.
Lancet (London, England).
2018 03; 391(10123):839-849. doi:
10.1016/s0140-6736(17)33095-7. [PMID: 29310899] - Kerri J Penrose, Chanson J Brumme, Maritsa Scoulos-Hanson, Kristen Hamanishi, Kelley Gordon, Raquel V Viana, Carole L Wallis, P Richard Harrigan, John W Mellors, Urvi M Parikh. Frequent cross-resistance to rilpivirine among subtype C HIV-1 from first-line antiretroviral therapy failures in South Africa.
Antiviral chemistry & chemotherapy.
2018 Jan; 26(?):2040206618762985. doi:
10.1177/2040206618762985. [PMID: 29566538] - Josep M Llibre, Hortensia Álvarez, Miguel Yzusqui. Clinical Impact of Virological Failure and Resistance Analysis Definitions used in Pivotal Clinical Trials of Initial Antiretroviral Treatment: A Systematic Review.
AIDS reviews.
2018; 20(3):158-170. doi:
10.24875/aidsrev.18000006. [PMID: 30264825] - Esteban Ribera. New Dual Combination of Dolutegravir-Rilpivirine for Switching to Maintenance Antiretroviral Therapy.
AIDS reviews.
2018; 20(4):179-186. doi:
10.24875/aidsrev.m18000026. [PMID: 30548024] - Rosario Palacios, M Mayorga, C M González-Domenech, C Hidalgo-Tenorio, C Gálvez, L Muñoz-Medina, J de la Torre, A Lozano, M Castaño, M Omar, Jesús Santos. Safety and Efficacy of Dolutegravir Plus Rilpivirine in Treatment-Experienced HIV-Infected Patients: The DORIVIR Study.
Journal of the International Association of Providers of AIDS Care.
2018 Jan; 17(?):2325958218760847. doi:
10.1177/2325958218760847. [PMID: 29529910] - José Luis Revuelta-Herrero, Esther Chamorro-de-Vega, Carmen Guadalupe Rodríguez-González, Roberto Alonso, Ana Herranz-Alonso, María Sanjurjo-Sáez. Effectiveness, Safety, and Costs of a Treatment Switch to Dolutegravir Plus Rilpivirine Dual Therapy in Treatment-Experienced HIV Patients.
The Annals of pharmacotherapy.
2018 Jan; 52(1):11-18. doi:
10.1177/1060028017728294. [PMID: 28836468] - Amedeo F Capetti, Maria V Cossu, Laura Paladini, Giuliano Rizzardini. Dolutegravir plus rilpivirine dual therapy in treating HIV-1 infection.
Expert opinion on pharmacotherapy.
2018 Jan; 19(1):65-77. doi:
10.1080/14656566.2017.1417984. [PMID: 29246084] - Minh P Lê, Linda Belarbi, Marie-Laure Chaix, Emmanuel Dulioust, Nadia Mahjoub, Dominique Salmon, Jean-Paul Viard, Claudine Duvivier, Gilles Peytavin, Odile Launay, Jade Ghosn. Penetration and antiviral efficacy of total and unbound maraviroc, raltegravir and rilpivirine in both female and male genital fluids from HIV-positive patients receiving regimens containing these antiretrovirals.
The Journal of antimicrobial chemotherapy.
2017 Nov; 72(11):3167-3171. doi:
10.1093/jac/dkx275. [PMID: 28961979] - Stein Schalkwijk, Angela Colbers, Deborah Konopnicki, Andrea Gingelmaier, John Lambert, Marchina van der Ende, José Moltó, David Burger. Lowered Rilpivirine Exposure During the Third Trimester of Pregnancy in Human Immunodeficiency Virus Type 1-Infected Women.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
2017 Oct; 65(8):1335-1341. doi:
10.1093/cid/cix534. [PMID: 28595298] - Joseph M Custodio, Susan K Chuck, Hoa Chu, Huyen Cao, Grace Ma, John Flaherty, John Ling, Brian P Kearney. Lack of clinically important PK interaction between coformulated ledipasvir/sofosbuvir and rilpivirine/emtricitabine/tenofovir alafenamide.
Pharmacology research & perspectives.
2017 10; 5(5):. doi:
10.1002/prp2.353. [PMID: 28971607] - David A Margolis, Juan Gonzalez-Garcia, Hans-Jürgen Stellbrink, Joseph J Eron, Yazdan Yazdanpanah, Daniel Podzamczer, Thomas Lutz, Jonathan B Angel, Gary J Richmond, Bonaventura Clotet, Felix Gutierrez, Louis Sloan, Marty St Clair, Miranda Murray, Susan L Ford, Joseph Mrus, Parul Patel, Herta Crauwels, Sandy K Griffith, Kenneth C Sutton, David Dorey, Kimberly Y Smith, Peter E Williams, William R Spreen. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial.
Lancet (London, England).
2017 Sep; 390(10101):1499-1510. doi:
10.1016/s0140-6736(17)31917-7. [PMID: 28750935] - Josef Reznicek, Martina Ceckova, Zuzana Ptackova, Ondrej Martinec, Lenka Tupova, Lukas Cerveny, Frantisek Staud. MDR1 and BCRP Transporter-Mediated Drug-Drug Interaction between Rilpivirine and Abacavir and Effect on Intestinal Absorption.
Antimicrobial agents and chemotherapy.
2017 09; 61(9):. doi:
10.1128/aac.00837-17. [PMID: 28696229] - Paula Arrabal-Durán, Carmen G Rodríguez-González, Esther Chamorro-de-Vega, Paloma Gijón-Vidaurreta, Ana Herranz-Alonso, María Sanjurjo-Sáez. Switching to a rilpivirine/emtricitabine/tenofovir single-tablet regimen in RNA-suppressed patients infected with human immunodeficiency virus 1: Effectiveness, safety and costs at 96 weeks.
International journal of clinical practice.
2017 Aug; 71(8):. doi:
10.1111/ijcp.12968. [PMID: 28722790] - Lei Wei, Hui-Ling Wang, Li Huang, Chin-Ho Chen, Susan L Morris-Natschke, Kuo-Hsiung Lee, Lan Xie. Drug-like property-driven optimization of 4-substituted 1,5-diarylanilines as potent HIV-1 non-nucleoside reverse transcriptase inhibitors against rilpivirine-resistant mutant virus.
Bioorganic & medicinal chemistry letters.
2017 06; 27(12):2788-2792. doi:
10.1016/j.bmcl.2017.04.068. [PMID: 28465101] - Marco Simiele, Alessandra Ariaudo, Amedeo De Nicolò, Fabio Favata, Martina Ferrante, Chiara Carcieri, Stefano Bonora, Giovanni Di Perri, Antonio De Avolio. UPLC-MS/MS method for the simultaneous quantification of three new antiretroviral drugs, dolutegravir, elvitegravir and rilpivirine, and other thirteen antiretroviral agents plus cobicistat and ritonavir boosters in human plasma.
Journal of pharmaceutical and biomedical analysis.
2017 May; 138(?):223-230. doi:
10.1016/j.jpba.2017.02.002. [PMID: 28219799] - Edwin DeJesus, Moti Ramgopal, Gordon Crofoot, Peter Ruane, Anthony LaMarca, Anthony Mills, Claudia T Martorell, Joseph de Wet, Hans-Jürgen Stellbrink, Jean-Michel Molina, Frank A Post, Ignacio Pérez Valero, Danielle Porter, YaPei Liu, Andrew Cheng, Erin Quirk, Devi SenGupta, Huyen Cao. Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study.
The lancet. HIV.
2017 05; 4(5):e205-e213. doi:
10.1016/s2352-3018(17)30032-2. [PMID: 28259776] - Chloe Orkin, Edwin DeJesus, Moti Ramgopal, Gordon Crofoot, Peter Ruane, Anthony LaMarca, Anthony Mills, Bernard Vandercam, Joseph de Wet, Jürgen Rockstroh, Adriano Lazzarin, Bart Rijnders, Daniel Podzamczer, Anders Thalme, Marcel Stoeckle, Danielle Porter, Hui C Liu, Andrew Cheng, Erin Quirk, Devi SenGupta, Huyen Cao. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study.
The lancet. HIV.
2017 05; 4(5):e195-e204. doi:
10.1016/s2352-3018(17)30031-0. [PMID: 28259777] - Marco Merli, Laura Galli, Letizia Marinaro, Alessandra Ariaudo, Emanuela Messina, Caterina Uberti-Foppa, Antonella Castagna, Antonio D'Avolio, Adriano Lazzarin, Stefano Bonora, Hamid Hasson. Pharmacokinetics of dolutegravir and rilpivirine in combination with simeprevir and sofosbuvir in HIV/hepatitis C virus-coinfected patients with liver cirrhosis.
The Journal of antimicrobial chemotherapy.
2017 03; 72(3):812-815. doi:
10.1093/jac/dkw492. [PMID: 27999010] - D Armenia, D Di Carlo, A Calcagno, G Vendemiati, F Forbici, A Bertoli, G Berno, S Carta, F Continenza, V Fedele, R Bellagamba, S Cicalini, A Ammassari, R Libertone, M Zaccarelli, V Ghisetti, M Andreoni, F Ceccherini-Silberstein, S Bonora, G Di Perri, A Antinori, C F Perno, M M Santoro. Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen.
The Journal of antimicrobial chemotherapy.
2017 03; 72(3):855-865. doi:
10.1093/jac/dkw512. [PMID: 27999048] - Manel Aouri, Catalina Barcelo, Monia Guidi, Margalida Rotger, Matthias Cavassini, Cédric Hizrel, Thierry Buclin, Laurent A Decosterd, Chantal Csajka. Population Pharmacokinetics and Pharmacogenetics Analysis of Rilpivirine in HIV-1-Infected Individuals.
Antimicrobial agents and chemotherapy.
2017 01; 61(1):. doi:
10.1128/aac.00899-16. [PMID: 27799217] - Dario Cattaneo, Davide Minisci, Valeria Cozzi, Agostino Riva, Paola Meraviglia, Emilio Clementi, Massimo Galli, Cristina Gervasoni. Dolutegravir plasma concentrations according to companion antiretroviral drug: unwanted drug interaction or desirable boosting effect?.
Antiviral therapy.
2017; 22(4):353-356. doi:
10.3851/imp3119. [PMID: 28008867] - Ian McGowan, Charlene S Dezzutti, Aaron Siegel, Jarret Engstrom, Alexiy Nikiforov, Kathryn Duffill, Cory Shetler, Nicola Richardson-Harman, Kaleab Abebe, David Back, Laura Else, Deidre Egan, Saye Khoo, James E Egan, Ronald Stall, Peter E Williams, Khaleel K Rehman, Amy Adler, Rhonda M Brand, Beatrice Chen, Sharon Achilles, Ross D Cranston. Long-acting rilpivirine as potential pre-exposure prophylaxis for HIV-1 prevention (the MWRI-01 study): an open-label, phase 1, compartmental, pharmacokinetic and pharmacodynamic assessment.
The lancet. HIV.
2016 12; 3(12):e569-e578. doi:
10.1016/s2352-3018(16)30113-8. [PMID: 27658864] - Teresa L Parsons, Mark A Marzinke. Development and validation of a liquid chromatographic-tandem mass spectrometric method for the multiplexed quantification of etravirine, maraviroc, raltegravir, and rilpivirine in human plasma and tissue.
Journal of pharmaceutical and biomedical analysis.
2016 Nov; 131(?):333-344. doi:
10.1016/j.jpba.2016.08.016. [PMID: 27632783] - Antonio Di Biagio, Niccolò Riccardi, Lucia Taramasso, Amedeo Capetti, Giovanni Cenderello, Alessio Signori, Paola Vitiello, Michele Guerra, Giuseppe Vittorio de Socio, Giovanni Cassola, Tiziano Quirino, Claudio Viscoli. Switch from unboosted protease inhibitor to a single-tablet regimen containing rilpivirine improves cholesterol and triglycerides.
International journal of antimicrobial agents.
2016 Nov; 48(5):551-554. doi:
10.1016/j.ijantimicag.2016.07.009. [PMID: 27566908] - Pasquale Pagliano, Tiziana Ascione, Maria Aurora Carleo, Giovanni Boccia, Francesco De Caro, Fabio Tortora. HIV positive patient with HSV-2 encephalitis: case report.
Le infezioni in medicina.
2016 Sep; 24(3):245-9. doi:
NULL. [PMID: 27668908] - James E Slaven, Brian S Decker, Angela D M Kashuba, Mohamed G Atta, Christina M Wyatt, Samir K Gupta. Plasma and Intracellular Concentrations in HIV-Infected Patients Requiring Hemodialysis Dosed With Tenofovir Disoproxil Fumarate and Emtricitabine.
Journal of acquired immune deficiency syndromes (1999).
2016 09; 73(1):e8-e10. doi:
10.1097/qai.0000000000001106. [PMID: 27285451] - Nicolas Hohmann, Raphael Reinhard, Sven Schnaidt, Lukas Witt, Alexandra Carls, Jürgen Burhenne, Gerd Mikus, Walter E Haefeli. Treatment with rilpivirine does not alter plasma concentrations of the CYP3A substrates tadalafil and midazolam in humans.
The Journal of antimicrobial chemotherapy.
2016 08; 71(8):2241-7. doi:
10.1093/jac/dkw125. [PMID: 27141088] - S Lambert-Niclot, C Allavena, M Grude, P Flandre, S Sayon, E Andre, M Wirden, A Rodallec, T Jovelin, C Katlama, V Calvez, F Raffi, A-G Marcelin. Usefulness of an HIV DNA resistance genotypic test in patients who are candidates for a switch to the rilpivirine/emtricitabine/tenofovir disoproxil fumarate combination.
The Journal of antimicrobial chemotherapy.
2016 08; 71(8):2248-51. doi:
10.1093/jac/dkw146. [PMID: 27231280] - Anna H Tran, Brookie M Best, Alice Stek, Jiajia Wang, Edmund V Capparelli, Sandra K Burchett, Regis Kreitchmann, Kittipong Rungruengthanakit, Kathleen George, Tim R Cressey, Nahida Chakhtoura, Elizabeth Smith, David E Shapiro, Mark Mirochnick. Pharmacokinetics of Rilpivirine in HIV-Infected Pregnant Women.
Journal of acquired immune deficiency syndromes (1999).
2016 07; 72(3):289-96. doi:
10.1097/qai.0000000000000968. [PMID: 26918544]